

Page 8, line 1: Please change "juniper tree" to -- *Juniper virginiana* --.

Page 8, line 7: Please change "in vivo" to -- in antigen-presenting cells --.

Page 8, line 22: After "T cell line", insert -- established from the patients --.

Page 12, line 1: Please change "p186-190" to --p186-200 --.

Page 12, line 7: Please change "5 residues" to -- 4 residues --.

Page 17, lines 5-6: Please change "DPA1-DPB1*0501" to -- DPA1*0101-DPB1*0501 --.

Page 22, line 6: After "dividing the level", please insert --(measured as counts-per-minute or cpm)--.

Page 23, line 16: After "even for", please insert -- Peptide No. 22 or No. 43 of Cry j 1 with --.

Page 30, line 8: Please change "six peptides" to -- five peptides --.

Page 31, line 7: Before "anti-human", please insert -- β -D-galactosidase-labeled --.

Page 31, line 17: Please change "peroxidase-labeled" to -- galactosidase-labeled --.

Page 34, line 17: After "peptide", please insert -- represented by SEQ ID NO: 1 --.

Page 38, line 2: Please change "(100 μ l)" to -- (200 μ l) --.

In the Claims

Please amend the following claims:

Claim 1 (Twice Amended): A peptide-based immunotherapeutic agent comprising a [multi-epitope peptide which is a linear polypeptide molecule comprising at least two different T cell epitope peptides that are derived from two or more different allergen molecules and are joined to each other via a peptide bond in an amount effective to prevent or treat allergic symptoms of a patient sensitive to the allergens, wherein]

[(1) each of said T cell epitope peptides reacts with T cell clones, respectively specific to the T cell epitope peptides, derived from the patient sensitive to said allergens;]

[(2) said multi-epitope peptide reacts dose-dependently with peripheral lymphocytes from the patient sensitive to the allergens;]

[(3) said multi-epitope peptide does not substantially react with allergen-specific IgE antibodies of the patient sensitive to the allergen(s); and]